The offering, the first IPO this year, attracted more than 32 billion dirhams ($3.5 bln) in demand for 500 million dirhams in shares. GSK seeks FDA nod for expanded use of RSV vaccine in adults ...

FDA head Marty Makary said the agency may fast-track drugs from companies that “equalize” the cost of medicines between the U ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Amid the sultry summer months, a few signs of fall become apparent, such as the appearance of school supplies on stores ...

The Europe Pharmaceutical Drugs Market size is valued at USD 450 billion in 2025 and is expected to reach USD 610 billion by ...

Scientists comment on reports that a child has died in a Liverpool hospital after contracting measles. Prof Sir Andrew Pollard FRCPCH FMedSci FRS, Director of the Oxford Vaccine Group, and Ashall ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

Moderna’s Covid vaccine for children has been given full FDA approval, making it the first such shot for kids in the U.S. that will no longer be administered under an emergency use authorization.

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Secretary Kennedy’s latest maneuver seeks to expand vaccine injury lawsuits, echoing a precarious time in U.S. history when ...